At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Transplant rejection
- Discontinued Rheumatoid arthritis
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 01 May 2000 Preclinical development for Transplant rejection in USA (Parenteral)
- 01 May 2000 An in vitro study has been added to the pharmacodynamics section of transplant rejection